Dylan F.

Regional Sales Specialist at OSSIO

Dylan F. is an experienced sales professional specializing in medical devices, with a focus on orthopedics, biologics, and infection prevention. Currently serving as a Regional Sales Specialist at OSSIO since August 2022, Dylan previously held the role of Sales Representative for Foot and Ankle at Paragon 28 from June 2020 to August 2022 and worked as a Medical Device Sales Representative at Modern Leap Medical from April 2018 to May 2020. Earlier career experience includes a position as a Data Analyst at F&G Analytics from February 2016 to January 2018. Dylan F. holds a Bachelor's Degree in Marketing Communications from Columbia College and has additional education from Suffolk University.

Location

Chicago, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


OSSIO

OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.


Employees

51-200

Links